IMM attending Bio-Europe Spring 17-19 March,Milan

Immupharma PLC

14 March 2025

 

                                                                                                                                                                         14 March 2025

ImmuPharma PLC

("ImmuPharma" or the "Company")

IMMUPHARMA ATTENDING BIO-EUROPE SPRING

 17-19 MARCH 2025, MILAN

Further opportunities to present recent insights into the MOA* of the P140 technology platform

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces that Tim McCarthy, CEO, Dr Tim Franklin, COO, and Dr Sebastien Goudreau, CEO of the R&D subsidiary ImmuPharma Biotech will be attending the Bio-Europe Spring Conference from 17-19 March 2025, in Milan.

BIO-Europe Spring is a premier partnering event in the biopharmaceutical and life sciences sector bringing together over 3,700 executives and facilitating more than 20,000 one-on-one meetings. It is an important opportunity for networking among biotech companies, pharmaceutical firms, investors, and academia.

Commenting on attendance at the Bio-Europe Spring conference, Tim McCarthy, CEO of ImmuPharma said: "Following on from positive discussions already held with a number of global BioPharma companies, we are focussed on continuing the momentum towards completing commercial deals across the portfolio."

*Mechanism of Action - update announcement issued on 13 March 2025 | https://www.immupharma.co.uk/news

Ends

For further information please contact: ImmuPharma PLC (www.immupharma.co.uk) Tim McCarthy, Chief Executive Officer Lisa Baderoon, Head of Investor Relations [phone] + 44 (0) 7721 413496 SPARK Advisory Partners Limited (NOMAD) Neil Baldwin Stanford Capital Partners (Joint Broker) Patrick Claridge, Bob Pountney SI Capital (Joint Broker) Nick Emerson [phone] [phone] [phone]

Notes to Editors

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140, is a unique non-immunosuppressive peptide for the treatment of SLE (Systemic Lupus Erythematosus) and CIDP (Chronic Idiopathic Demyelinating Polyneuropathy) and preclinical models suggest therapeutic activity for many other autoimmune diseases.

For additional information about ImmuPharma please visit www.immupharma.co.uk

ImmuPharma's LEI (Legal Entity Identifier) code : 213800VZKGHXC7VUS895.

About Reach announcements

Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases such as marketing messages, corporate and product information into the public domain. An RNS Regulatory announcement is required to be notified under the AIM Rules for Companies.

 

END